IPF Cough: Opioid-Based Approach Tested - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

IPF Cough: Opioid-Based Approach Tested

Researchers examine oral nalbuphine for chronic cough in IPF, using objective digital monitoring and patient-reported measures.

  • By

  • Kathryn Wighton

  • January 28, 2026

  • 3 min

Share

Clinical Scorecard: IPF Cough: Opioid-Based Approach Tested

At a Glance

CategoryDetail
ConditionIdiopathic Pulmonary Fibrosis (IPF) with Chronic Cough
Key MechanismsOral κ-opioid receptor agonist (nalbuphine) targeting cough frequency
Target PopulationAdults with IPF and chronic cough lasting at least 8 weeks
Care SettingMultinational, randomized, double-blind, placebo-controlled clinical trial

Key Highlights

  • Dose-dependent reductions in cough frequency observed with nalbuphine
  • 60% reduction in cough frequency with 108 mg dose at 6 weeks
  • Improvements in cough severity and quality of life in higher dose groups
  • Study involved 165 patients across 52 sites in 10 countries
  • Common adverse events included nausea, vomiting, and dizziness

Guideline-Based Recommendations

Diagnosis

  • Cough severity numerical rating scale score of 4 or higher
  • Prespecified pulmonary function criteria must be met

Management

  • Consider nalbuphine extended release for chronic cough in IPF patients

Monitoring & Follow-up

  • Continuous digital cough monitoring for 24 hours to assess cough frequency

Risks

  • Mild adverse events primarily during dose titration, potential for bias in missing data

Patient & Prescribing Data

Median age 71 years, 72% male, 77% on antifibrotic therapy

Effective cough frequency reduction observed with higher nalbuphine doses

Clinical Best Practices

  • Monitor patients for adverse events during dose titration
  • Assess patient-reported outcomes alongside objective cough measurements
  • Consider long-term efficacy and safety in future studies

Related Resources & Content

Original Source(s)

IPF Cough: Opioid-Based Approach Tested

  • by Kathryn Wighton

  • January 28, 2026

Related Content

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”

Association between objective sleep structure and suicidal ideation in patients with depression: a study based on polysomnographic regression and cluster analysis

Side Effects: The Body Keeps Score

Turns out biology tracks more than we thought — from a spit test that reads your all-nighter to a surgical outcome that still shows up in household chores two decades later. Plus: habits aren't built gradually. They snap.